People who inject drugs (PWID) comprise one of the major transmission risk groups for human immunodeficiency virus (HIV) and hepatitis C virus (HCV). In 2011, Athens experienced a large HIV outbreak among PWID. Significant public health interventions were implemented in response to the HIV outbreak. The aims of this study were to estimate the indirect effects of the HIV interventions on HCV infection and to evaluate the concept of the association between HCV and HIV infections in the case of Athens. A dynamic, stochastic, individual-based model was developed to simulate HCV transmission among PWID. We calibrated the model to reproduce the observed HCV prevalence among PWID in Greece. Two years prior to the HIV outbreak, an undetected HCV outbreak has occurred. In 2009, the incidence of HCV infection increased from 640 (495, 842) cases in 2008 to 1260 (1060, 1500). The mean time from initiation of injecting drug use to HCV acquisition decreased from 29 months in 2008 to 13 months in 2009. After HIV interventions, HCV incidence declined by 64.8% in 2012, compared to 2009. The averted HCV incidence cases attributed to the HIV-implemented interventions were 2200 (1950, 2480), during 2012-2015. The cumulative number incident HCV cases in Athens during 2002-2015 was about 9900 (7800, 12 100). Our results highlight that before the 2011 HIV outbreak in Athens, an HCV outbreak occurred in 2009. Prevention measures for HIV that took place in the Athens metropolitan area in 2012 reduced significantly the incidence of HCV.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jvh.13178 | DOI Listing |
BMC Health Serv Res
January 2025
Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA.
Background: Despite their ubiquity across sub-Saharan Africa, private pharmacies are underutilized for HIV service delivery beyond the sale of HIV self-test kits. To understand what uptake of HIV prevention and treatment services might look like if private pharmacies offered clients free HIV self-testing and referral to clinic-based HIV services, we conducted a pilot study in Kenya.
Methods: At 20 private pharmacies in Kisumu County, Kenya, pharmacy clients (≥ 18 years) purchasing sexual health-related products (e.
PLoS One
January 2025
School of Public Health and Social Sciences, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Background: Adherence to HIV treatment regimens involves the consistent and correct intake of all prescribed medications. The implementation of antiretroviral therapy (ART) program has significantly reduced mortality among adolescents living with HIV. However, adherence to ART is lower among adolescents compared to other sub-populations and even lower in sub-Saharan Africa.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Cape Town, Cape Town, South Africa.
Background: Accurate assessment of cognitive impairment in low-income settings may require consideration of complex psychosocial variables (PV). Failure to consider the association of PV with biological factors, such as HIV, could lead to false classification of cognitive impairment. We investigated the impact of PV on cognitive performance in people with HIV (PWH) and without in a low-income area of Cape Town, South Africa.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Addis Ababa University, Addis Ababa, CA, Ethiopia; Global Brain Health Institute, University of California, San Francisco, CA, USA.
Background: Vitamin D deficiency is linked with the risk of developing dementia and Alzheimer disease. There is paucity of data on serum vitamin D level among patients from tropical countries such as Ethiopia. The objective of this study is to determine the prevalence of vitamin D deficiency and associated factors among Alzheimer disease and related dementia patients in Ethiopia.
View Article and Find Full Text PDFClin Infect Dis
January 2025
ISARIC - Pandemic Sciences Institute, University of Oxford, United Kingdom.
Background: The global mpox outbreak which started in May 2022 was caused by a novel clade IIb variant of the mpox virus (MPXV). It differed from the traditional Western and Central Africa disease in transmission patterns and clinical presentation.
Methods: To address the need for detailed clinical and virologic data, we conducted an observational cohort study (MOSAIC) during May 2022-July 2023 in individuals with confirmed MPXV infection enrolled in six European Countries.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!